Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
MicroDose Therapeutx General Information
MicroDose Therapeutx developed a proprietary dry powder inhaler technology and several pipeline products. Their lead compound MDT-637 for RSV reached Phase 2 clinical trials. The company was acquired by Teva Pharmaceuticals in 2013.
Contact Information
Primary Industry
Biotech
Corporate Office
Monmouth Junction, New Jersey
United States
United States
Drug Pipeline
MDT-637
DiscontinuedKey Partnerships
Novartis, ViroPharma Incorporated
MicroDose Therapeutx Funding
No funding data available
To view MicroDose Therapeutx's complete valuation and funding history, request access »